Antidepressants for Migraine Prevention
Antidepressants — particularly tricyclics and SNRIs — are established options for migraine prevention, especially when headache coexists with depression, anxiety, insomnia, or chronic pain. The doses used for migraine are generally lower than those needed for depression. SSRIs, despite their widespread use, have minimal evidence for migraine prevention and should not be prescribed for that purpose alone.
Bottom Line
- Amitriptyline (25-75 mg at bedtime): Level B. Most evidence among antidepressants for migraine. Best when comorbid insomnia, tension-type headache, or chronic daily headache.
- Venlafaxine ER (150 mg/day): Level B. Best when comorbid depression or anxiety and the patient cannot tolerate TCA side effects.
- Nortriptyline (25-75 mg): Commonly used as an alternative to amitriptyline with fewer anticholinergic and sedating effects. Less direct trial evidence but widely accepted.
- SSRIs (fluoxetine, sertraline, etc.): NOT effective for migraine prevention. Do not prescribe for headache alone.
- Migraine doses are sub-antidepressant — amitriptyline 25-50 mg for migraine vs 100-300 mg for depression. The mechanism in migraine likely involves serotonergic and noradrenergic modulation independent of mood effects.
Tricyclic Antidepressants
Amitriptyline
The most-studied antidepressant for migraine prevention, with evidence from multiple RCTs dating back to the 1970s.
Evidence
- Couch & Hassanein (1979): First major RCT; amitriptyline 50-100 mg/day reduced migraine frequency by ~40% vs placebo
- Ziegler et al. (1987): Amitriptyline was equivalent to propranolol in migraine prevention
- Cochrane Review (Jackson 2015): Pooled analysis confirmed benefit with NNT ~4 for ≥50% responder rate; quality of evidence was moderate
- AAN/AHS (2012): Level B (probably effective)
Dosing
Amitriptyline: Practical Prescribing
- Start: 10 mg at bedtime (especially in elderly or sensitive patients)
- Titrate: Increase by 10 mg every 1-2 weeks
- Target: 25-50 mg at bedtime for migraine; some patients benefit up to 75 mg
- Onset: 4-6 weeks at therapeutic dose
- Take at bedtime — sedation is both a side effect and a feature (helps comorbid insomnia)
- Morning drowsiness ("hangover") is the most common tolerability issue; moving the dose to earlier in the evening (e.g., 8 PM) can help
Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Sedation / morning drowsiness | Very common | Often decreases after 1-2 weeks; take earlier in evening |
| Dry mouth | Common | Anticholinergic; sugar-free gum or lozenges |
| Weight gain | Common (2-4 kg) | Increased appetite; more pronounced than beta-blockers |
| Constipation | Common | Anticholinergic |
| Urinary retention | Uncommon | Avoid in BPH |
| Orthostatic hypotension | Uncommon at migraine doses | More problematic in elderly; fall risk |
| QT prolongation / cardiac conduction | Dose-dependent | ECG recommended in patients >40 years or with cardiac risk factors; avoid in pre-existing prolonged QT |
| Cognitive impairment | Uncommon at low doses | More relevant in elderly (anticholinergic burden) |
Nortriptyline
Nortriptyline is the active metabolite of amitriptyline. It is widely used as a "cleaner" TCA alternative with less sedation, less anticholinergic load, and less weight gain.
- Evidence: No large RCTs specifically for migraine; however, it is accepted as equivalent to amitriptyline by expert consensus and is included in AHS treatment guidelines
- Dosing: 10 mg at bedtime, titrate to 25-75 mg. Same titration approach as amitriptyline.
- Preferred over amitriptyline in patients sensitive to sedation or anticholinergic effects, and in elderly patients (lower anticholinergic burden)
Other TCAs
| Agent | Evidence | Notes |
|---|---|---|
| Doxepin | Limited | Sometimes used at very low doses (3-6 mg) for insomnia; migraine benefit at higher doses is uncertain |
| Protriptyline | Very limited | Activating rather than sedating; rarely used |
| Imipramine | Small positive studies | Less commonly used than amitriptyline; no clear advantage |
TCA Safety Considerations
- Lethal in overdose — prescribe with caution in patients with suicidal ideation; limit dispensed quantity if concern exists
- Serotonin syndrome risk when combined with triptans, SSRIs, SNRIs, or MAOIs. At migraine doses (10-75 mg) the risk with triptans is very low (FDA alert controversial); monitoring is reasonable but the combination is commonly used in practice.
- Anticholinergic burden in elderly — contributes to cognitive impairment, falls, urinary retention. Use nortriptyline or consider a non-TCA alternative.
- Avoid combining with other QT-prolonging drugs without ECG monitoring
SNRIs
Venlafaxine
Venlafaxine is the best-studied SNRI for migraine prevention and the preferred antidepressant when the patient also needs treatment for depression or generalized anxiety disorder.
Evidence
- Ozyalcin et al. (2005): Venlafaxine ER 150 mg/day reduced migraine frequency by 50-60%, comparable to amitriptyline 75 mg/day
- Bulut et al. (2004): Venlafaxine ER 75-150 mg/day showed significant benefit over placebo
- AAN/AHS (2012): Level B (probably effective) at 150 mg/day
- Also effective for vestibular migraine and chronic daily headache in open-label series
Dosing
- Start: Venlafaxine ER 37.5 mg daily
- Titrate: Increase to 75 mg after 1 week, then to 150 mg after another 1-2 weeks
- Target: 150 mg/day (the dose with best migraine evidence)
- At doses <150 mg, venlafaxine acts primarily as an SSRI; noradrenergic effects emerge at ≥150 mg — this is likely important for migraine efficacy
Side Effects
- Nausea: Most common early side effect (start low, take with food, usually resolves in 1-2 weeks)
- Hypertension: Dose-dependent; monitor blood pressure, especially at doses ≥150 mg
- Insomnia / activation: Take in the morning; opposite profile to amitriptyline
- Sexual dysfunction: Similar to SSRIs
- Discontinuation syndrome: Venlafaxine has the most severe withdrawal of any antidepressant. Taper very slowly (reduce by 37.5 mg every 1-2 weeks). Warn patients never to stop abruptly.
- Weight: Neutral at lower doses; modest gain at higher doses in some patients
Duloxetine
- Evidence for migraine: No RCTs specifically for migraine prevention
- May be useful when migraine coexists with fibromyalgia, chronic pain, or diabetic neuropathy (FDA-approved for these)
- Dosing: 30-60 mg daily; some use up to 120 mg
- Clinical experience suggests modest migraine benefit; less robust than venlafaxine
SSRIs: Why They Don't Work for Migraine
Despite their widespread use for depression and anxiety, SSRIs have minimal to no evidence for migraine prevention.
- Fluoxetine: Conflicting results. One positive trial at 20 mg/day; multiple negative trials. AAN rated as Level C (possibly effective) but most headache specialists do not recommend it.
- Sertraline, paroxetine, citalopram, escitalopram: No evidence of migraine prevention benefit
- Mechanism: Migraine prevention likely requires noradrenergic activity (present in TCAs and venlafaxine ≥150 mg), not pure serotonin reuptake inhibition
Choosing an Antidepressant for Migraine
- Insomnia + migraine: Amitriptyline (sedation is therapeutic)
- Coexisting tension-type headache or chronic daily headache: Amitriptyline or nortriptyline
- Depression/anxiety + migraine: Venlafaxine ER 150 mg (treats both at therapeutic doses)
- Elderly or anticholinergic-sensitive: Nortriptyline (lower burden) or venlafaxine
- Obesity concern: Venlafaxine (weight-neutral) over amitriptyline (weight gain)
- Chronic pain comorbidity (fibromyalgia, neuropathy): Duloxetine or venlafaxine
- Patient already on an SSRI for depression: Can add low-dose nortriptyline for migraine (monitor for serotonin syndrome), or switch to venlafaxine to cover both
Comparison Table
| Agent | Evidence | Migraine Dose | Key Advantage | Key Limitation |
|---|---|---|---|---|
| Amitriptyline | Level B | 25-75 mg HS | Insomnia benefit; effective for mixed headache types | Sedation, weight gain, anticholinergic effects |
| Nortriptyline | Consensus | 25-75 mg HS | Less sedation/anticholinergic than amitriptyline | Less direct trial evidence |
| Venlafaxine ER | Level B | 150 mg daily | Treats comorbid depression/anxiety; weight-neutral | Severe discontinuation syndrome; hypertension |
| Duloxetine | Limited | 60 mg daily | Comorbid chronic pain / fibromyalgia | No migraine RCTs |
| Fluoxetine | Level C | 20 mg daily | Weight-neutral; activating | Conflicting evidence; most studies negative |
| Other SSRIs | No evidence | — | — | Not effective for migraine |
References
- Silberstein SD, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337-1345.
- Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36(11):695-699.
- Jackson JL, et al. Tricyclic and tetracyclic antidepressants for the prevention of frequent episodic or chronic tension-type headache in adults: a systematic review and meta-analysis. J Gen Intern Med. 2017;32(12):1351-1358.
- Ozyalcin SN, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45(2):144-152.
- Bulut S, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107(1):44-48.
- Banzi R, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015;(4):CD002919.